Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709162 · ClinicalTrials.gov registry record · Phase 2
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01709162 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 31 participants.
The verdict
NCT01709162, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.
Interventions
- DRUG Chemotherapy
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01709162
The ClinicalTrials.gov registry entry for NCT01709162 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT01709162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01709162 about?
NCT01709162 is a clinical study titled "Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma". The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.
What is the current status of trial NCT01709162?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2013-03. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01709162?
The interventions under investigation include: Chemotherapy (DRUG), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01709162?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.